作者:Siraj M Ali , Alexa B Schrock ...
来源:[J].Lung Cancer: Targets and Therapy, 2018, Vol.2018 (default), pp.45-47Dove
摘要:In non-small cell lung cancer (NSCLC) refractory to standard therapy and which lacks well known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in NSCLC may be sensitizing to ana...
作者:... Bryan S Benn , Siraj M Ali , Sai-Hong Ignatius Ou
来源:[J].Lung Cancer: Targets and Therapy, 2018, Vol.2018 (default), pp.111-116Dove
摘要:Anaplastic lymphoma kinase (ALK)-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutatio...
作者:... Alexa B Schrock , Siraj M Ali , Sai-Hong Ignatius Ou
来源:[J].Lung Cancer: Targets and Therapy, 2019, Vol.2019 (default), pp.21-26Dove
摘要:Exploring resistance mechanisms in patients with EGFR-mutant non-small cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies. Here we report a case ...


资源合作, +86-10-82896619   意见反馈